Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
AuteursModi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D
In vitro and in vivo validation studies of optimized iron oxide nanoparticles carrying targeting ligands for a new therapeutic strategy in head and neck cancers.
AuteursFurgiuele S, Gevart T, Freis B, Ramirez MLA, Descamps G, Boutry S, Larbanoix L, Sant'Angelo D, Trelcat A, Saussez S, Bégin-Colin S, Journe F, Laurent S
Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.
AuteursBergiers I, Köse MC, Skerget S, Malfait M, Fourneau N, Ellis JC, Vanhoof G, Smets T, Verbist B, De Maeyer D, Van Houdt J, Van der Borght K, Verona R, Heidrich B, Kurth W, Delforge M, Meuleman N, Van Droogenbroeck J, Vlummens P, Heuck CJ, Beguin Y, Bahlis N, Casneuf T, Caers J
